---
id: idsa-shea-cdiff-2021
title: "IDSA/SHEA 2021 Focused Update Guidelines on Management of Clostridioides difficile Infection in Adults"
short_title: "IDSA/SHEA C. diff 2021"

organization: Infectious Diseases Society of America
collaborators:
  - Society for Healthcare Epidemiology of America
country: US
url: https://www.idsociety.org/practice-guideline/clostridioides-difficile-2021-focused-update/
doi: 10.1093/cid/ciab549
pmid: 34164674
open_access: true

specialty: infectious-disease
guideline_type: clinical-practice
evidence_system: GRADE
conditions:
  - Clostridioides difficile infection
  - CDI
  - C. diff colitis
  - antibiotic-associated diarrhea
tags:
  - fidaxomicin
  - vancomycin
  - bezlotoxumab
  - recurrent CDI
  - fecal microbiota transplant

publication_date: 2021-06-24
previous_version_date: 2017-02-15
status: current
supersedes: idsa-shea-cdiff-2017
superseded_by: null

pdf_path: null
has_pdf: false
last_reviewed: 2025-12-21
---

## Scope

Focused update on management of C. difficile infection in adults, specifically addressing fidaxomicin and bezlotoxumab for treatment of initial and recurrent CDI.

## Notes

Updates 2017 guideline. Key change: fidaxomicin now recommended as preferred treatment over vancomycin for initial and recurrent CDI.
